SoliPharma of Hangzhou Raises $36.5 Million to Develop High End Generics
publication date: Sep 11, 2019
SoliPharma, a Hangzhou company, completed a $36.5 million financing to support its development of high-end, difficult-to-make generic drugs. The company, founded in 2010, develops products with partners, and registers them in China and the US, with an eye toward global markets over time. Its expertise ranges from early API development, through product development and into regulatory approval. The company's SoliTech® Solutions division has been given the mission of “bringing challenging molecules to global markets” more quickly. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.